Download the ESMO 2012 Abstract Book - Oxford Journals

Annals of Oncology subject index
antiprogressive treatment, ix303 (919P)
antitumor activity, ix361 (1109O), ix405
(1237PD), ix157 (453P), ix160 (461P), ix258
(784O)
anthracycline induced left ventricle dysfunction
prediction, ix513 (1593P)
AP26113, ix152 (439O)
aplastic anemia, ix357 (1095)
apoptosis, ix365 (1122P), ix72 (165), ix197
(575P), ix253 (769)
appendix carcinoma, ix222 (661)
aprepitant, ix500 (1550PD), ix509 (1578P)
ARN-509, ix303 (920P)
aromatase inhibitor, ix27 (14IN), ix28 (17IN),
ix104 (277P), ix105 (280P), ix105 (282P), ix124
(342P)
ARQ 197, ix225 (669PD)
array CGH, ix71 (161P)
arthralgia, ix113 (310)
asbestos exposure, ix469 (1447PD)
ASG-5ME, ix317 (963TiP)
ASPS, ix484 (1495P)
assessment, ix517 (1607P)
association, ix260 (787O)
asymptomatic brain metastases, ix137 (387)
asymptomatic distant metastasis, ix106 (285P)
aurora A kinase inhibitor, ix160 (461P)
Aurora A kinase, ix168 (489P)
Aurora-A, ix134 (376)
autologous stem cell transplantation, ix353
(1082P), ix353 (1083P), ix354 (1084P), ix260
(789O)
autologous transplantation, ix354 (1086P)
automated quantitative protein expression analysis
(AQUA), ix534 (1666P)
autophagy, ix538 (1679P)
avb3 integrin, ix86 (214P)
awareness and willingness to participate, ix450
(1381P)
Awareness, ix472 (1458P)
axitinib, ix409 (1246P), ix453 (1391P), ix268
(811P), ix279 (843P), ix283 (856P)
ayurveda, ix452 (1388P)
5-azacytidine, ix357 (1096)
B
53BP1, ix533 (1661P), ix229 (686P)
B-cell receptor, ix44 (65IN)
bacteremia, ix503 (1559P)
BAP 1, ix427 (1300P)
barriers, ix65 (136IN)
basal cell carcinoma, ix477 (1474)
basal cell nevus syndrome, ix477 (1474)
base of tongue squamous cell carcinoma, ix339
(1032P)
Bax, ix212 (628)
BCC, ix362 (1111PD), ix362 (1112PD)
BDNF, ix474 (1464P), ix79 (188P)
BELIEF, ix58 (105IN)
belinostat, ix349 (1068PD)
Belotean, ix492 (1520PD)
bendamustine, ix348 (1064O)
benefit, ix332 (1014)
best response, ix282 (852P)
bevacizumab beyond progression, ix140 (400),
ix192 (562P), ix220 (655)
bevacizumab, ix118 (323PD), ix220 (653), ix378
(1159P), ix378 (1160P), ix390 (1194P), ix405
(1236PD), ix406 (1239P), ix406 (1240P), ix419
(1277P), ix419 (1278P), ix420 (1279P), ix426
(1299P), ix428 (1303P), ix441 (1351), ix441
(1352), ix441 (1353), ix445 (1364TiP), ix70
(155P), ix529 (1648P), ix530 (1653P), ix531
(1657P), ix75 (174O), ix81 (198P), ix85 (209P),
ix108 (292P), ix116 (317O), ix122 (335P), ix125
(345P), ix127 (354P), ix128 (356P), ix139 (395),
ix146 (417PD), ix151 (437TiP), ix161 (464P),
ix171 (499P), ix181 (530PD), ix182 (532P),
ix189 (555P), ix190 (559P), ix191 (560P), ix193
(565P), ix193 (567P), ix195 (571P), ix196
(573P), ix202 (592P), ix202 (594P), ix203
(596P), ix206 (607P), ix209 (618), ix211 (624),
ix218 (648), ix219 (651), ix219 (652), ix221
(659), ix249 (755), ix267 (809P), ix289 (876),
ix319 (967O), ix320 (973PD), ix322 (978P),
ix325 (986P)
beyond PD, ix439 (1343), ix439 (1344)
BEZ235, ix157 (454P)
BI-RADS classification, ix107 (286P)
BIBF 1120, ix245 (740P), ix246 (744P)
bilateral breast cancer, ix175 (513PD)
biliary tract cancer, ix241 (725P), ix242 (730P),
ix242 (731P), ix245 (739P)
biliary tract cancers, ix254 (773)
bioavailability, ix507 (1574P)
biobank, ix385 (1179O), ix535 (1669P)
Biobanking, ix61 (117IN)
biochemotherapy, ix373 (1147)
bioequivalence, ix507 (1574P)
biological characteristics, ix215 (638)
biological marker, ix85 (211P)
biological markers, ix474 (1464P)
biological response, ix354 (1086P), ix303 (919P)
biological therapy, ix500 (1550PD)
biology of colorectal cancer, ix92 (236)
biomarker discovery, ix262 (794PD)
biomarker, ix451 (1382P), ix529 (1647PD), ix531
(1656P), ix531 (1657P), ix73 (169O), ix77
(180P), ix78 (186P), ix81 (198P), ix83 (202P),
ix84 (206P), ix88 (220P), ix89 (226P), ix93
(238), ix93 (240), ix158 (457P), ix173 (505),
ix187 (550P), ix212 (628), ix263 (796PD), ix275
(832P), ix278 (842P), ix285 (861P), ix300
(910P)
biomarkers for antihormone responsiveness, ix96
(249PD)
biomarkers, ix59 (110IN), ix383 (1173P), ix390
(1194P), ix400 (1226O), ix405 (1236PD), ix406
(1239P), ix406 (1240P), ix430 (1312), ix529
(1648P), ix47 (1703IN), ix76 (177PD), ix78
(183P), ix80 (194P), ix84 (207P), ix86 (213P),
ix87 (219P), ix32 (28IN), ix124 (343P), ix259
(785O), ix49 (78IN), ix301 (915P)
biomolecular analysis, ix483 (1491P)
biosimilar, ix351 (1074P), ix103 (274P)
biosimilars, ix504 (1563P), ix506 (1568P), ix506
(1569P)
biotherapeutics, ix488 (1508P)
bispecific monoclonal antibody, ix350 (1072P)
bispecific, ix170 (496P)
bisphosphates, ix443 (1359)
bisphosphonate, ix511 (1584P), ix511 (1585P)
bisphosphonates, ix524 (1633)
biweekly carboplatin and paclitaxel, ix422 (1285P)
BKM120, ix116 (318O), ix157 (454P), ix223
(664TiP)
bladder cancer, ix39 (50IN), ix39 (53IN), ix260
(788O), ix264 (799P), ix265 (802P), ix266
(805P), ix266 (806P), ix266 (807P), ix290 (882),
ix291 (884), ix291 (885)
bladder preservation, ix265 (801P), ix291 (883)
bladder, ix93 (239), ix265 (803P)
bleomycin, ix347 (1061TiP), ix285 (862P)
blood flow in tumor, ix134 (379)
blood pressure monitoring, ix268 (811P)
blood vessels, ix149 (431)
blood–brain barrier, ix537 (1675P)
blood-brain barrier permeability, ix61 (120IN)
BOADICEA, ix34 (35IN)
body composition, ix168 (491P)
Body Mass Index (BMI), ix206 (606P)
body mass index, ix515 (1599P), ix119 (327PD),
ix135 (380)
bone disease, ix126 (351P)
bone growth, ix526 (1642)
bone health, ix449 (1377P)
bone marker, ix126 (351P)
bone marrow transplantation, ix357 (1095)
bone marrow, ix69 (152P)
bone metastases, ix447 (1372P), ix509 (1580P),
ix510 (1583P), ix511 (1585P), ix133 (372P),
ix140 (401), ix309 (937P)
Bone Metastasis, c-MET, ix296 (897O)
bone metastasis, ix344 (1050P), ix432 (1320),
ix433 (1321), ix443 (1359), ix126 (348P), ix229
(685P)
bone metastatic patients, ix524 (1633)
bone mineral density, ix105 (282P)
bone resorption biomarker, ix432 (1320)
bone turnover markers, ix266 (805P), ix312 (945)
bone-targeted treatment, ix38 (49IN)
borderline ovarian cancer, ix322 (976P)
borderline subgroup (12-20% split signals), ix390
(1195P)
bortezomib, ix348 (1064O), ix249 (754)
bowel obstruction, ix326 (992P)
brachytherapy, ix329 (1003P)
BRAF inhibitor, ix366 (1125P)
BRAF mutation, ix365 (1123P), ix373 (1145),
ix383 (1173P), ix94 (242), ix220 (656)
BRAF status, ix383 (1173P)
BRAF-mutations, ix373 (1147)
BRAF, ix387 (1187P), ix529 (1649P), ix196
(574P), ix216 (641), ix46 (69IN), ix46 (70IN)
brain metastases, ix366 (1125P), ix369 (1132P),
ix394 (1207P), ix61 (120IN), ix62 (123IN),
ix421 (1283P), ix421 (1284P), ix428 (1305P),
ix435 (1330), ix446 (1368TiP), ix489 (1514),
ix537 (1675P), ix31 (26IN), ix144 (412O), ix145
(414PD), ix148 (427P), ix148 (428P), ix150
(433), ix253 (771)
brain metastasis, ix62 (121IN), ix414 (1262P)
brain, ix221 (660)
BRCA 1/2 mutations, ix109 (294P)
BRCA mutation, ix176 (515P), ix319 (969PD)
BRCA1/2, ix469 (1449PD), ix34 (35IN), ix175
(512PD), ix175 (513PD)
BRCA1, ix498 (1542TiP), ix531 (1655P), ix533
(1661P), ix34 (34IN), ix229 (686P), ix266
(807P)
BRCA2 mutation, ix176 (514P)
BRCA2, ix34 (34IN)
breakthrough cancer pain (BTcP), ix518 (1612P)
breast cancer screening, ix469 (1449PD)
Breast Cancer Stem Cells (BCSCs), ix133 (375P)
breast cancer stem cells, ix110 (300)
breast cancer subtypes, ix100 (261P), ix110
(297P), ix131 (366P)
breast cancer, HER2, EGFR, ix127 (353P)
breast cancer, ix57 (100IN), ix57 (101IN), ix57
(102IN), ix58 (103IN), ix58 (104IN), ix59
(108IN), ix384 (1178TiP), ix61 (120IN), ix62
(121IN), ix452 (1388P), ix453 (1389P), ix454
(1393P), ix454 (1394P), ix455 (1397P), ix455
(1398P), ix27 (13IN), ix460 (1417PD), ix470
(1450P), ix470 (1451P), ix67 (146P), ix477
(1476), ix501 (1552P), ix501 (1553P), ix506
(1568P), ix70 (156P), ix513 (1593P), ix27
(15IN), ix521 (1621), ix525 (1636), ix72 (164),
ix531 (1656P), ix532 (1658P), ix532 (1660P),
ix543 (1698P), ix74 (172O), ix29 (18IN), ix82
(200P), ix83 (202P), ix84 (204P), ix84 (206P),
ix87 (216P), ix87 (217P), ix94 (243), ix95
(246O), ix96 (249PD), ix96 (250PD), ix97
(253PD), ix97 (254PD), ix100 (261P), ix100
(264P), ix101 (265P), ix101 (266P), ix101
(268P), ix102 (269P), ix102 (270P), ix103
(273P), ix104 (276P), ix104 (277P), ix104
(278P), ix105 (279P), ix105 (281P), ix106
(283P), ix106 (284P), ix107 (286P), ix107
(288P), ix108 (290P), ix109 (293P), ix110
(297P), ix110 (299), ix110 (300), ix111 (302),
ix112 (305), ix112 (306), ix112 (308), ix113
(309), ix113 (311), ix114 (313), ix114 (314),
Volume 23 | Supplement 9 | September 2012 doi:10.1093/annonc/mds467 | ix587